Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.

Rhonda L Bitting Janet A Tooze Michael Goodman Donald C Vile Jessica M Brown Christopher Y Thomas Morgan Neve Mitra Kooshki Safoa Addo Pierre L Triozzi Purnima Dubey

Published in: Cancer research communications (2024)

We found that combining pembrolizumab with low-dose paclitaxel may be effective in patients with urothelial carcinoma progressing on platinum chemotherapy, with favorable safety profiles.

Keyphrases

low dose
advanced non small cell lung cancer
high dose
chemotherapy induced
locally advanced
epidermal growth factor receptor
rectal cancer